Summit Therapeutics cancer drug rejection raises risks for China biotech expansion

Traders Union
All News
Regulators
Summit cancer drug rejection

Highlights

FDA rejected Summit Therapeutics' Ivonescimab cancer drug, citing insufficient evidence of effectiveness and no significant survival rate improvement.
Akeso, which licensed Ivonescimab to Summit in a deal worth up to $5bn, has seen its shares fall 27 per cent in 2026 after the setback.
Regulatory scrutiny on Chinese biotech increased, as U.S. lawmakers urged the FDA to tightly monitor or restrict use of Chinese drug trial data for approvals.

FDA decision and deal background

As reported by Financial Times, Miami-based Summit Therapeutics said on Sunday that the Food and Drug Administration rejected its Ivonescimab cancer drug, concluding that substantial evidence of effectiveness was not established and that the treatment did not significantly add to survival rates.

Summit licensed the drug from Zhongshan-based Akeso in 2022 in a deal worth up to $5bn. The application was one of the first that Summit filed with the FDA for Ivonescimab across a broader range of cancer treatments, and the partnership had been widely viewed as a test case for whether medicines developed in China could meet U.S. regulatory standards.

"We are disappointed for patients and their families awaiting additional treatment options in this setting," Summit co-chief executive Robert Duggan said in a statement. Analysts said the rejection is not surprising and may not affect the company's other applications for the drug with the agency.

Implications for Chinese biotech and U.S. oversight

The study submitted to the FDA included 62 per cent Asian patients and 38 per cent western patients. TD Cowen said in a research report on Sunday that the patient mix may have influenced the FDA's decision-making, noting that the agency has previously rejected Chinese clinical studies that it viewed as not representative of the U.S. population.

Akeso is regarded as one of the leading groups in China's fast-growing biotech sector and received a prominent presentation slot at the American Society of Clinical Oncology in June. Its shares are down 27 per cent so far in 2026, while the FDA setback is likely to deepen investor attention on how Chinese drugmakers generate data for overseas approvals.

Regulatory and political scrutiny in the U.S. is also increasing. The former head of the FDA said earlier this year that China represents the biggest threat in the drug space, and in August lawmakers from both parties urged the agency to stop using drug trial data from China for new clinical trials or drug applications unless the FDA has inspected the trial site within the previous 12 months.

Summit's ties to larger industry players also underline the case's importance for the sector. AstraZeneca invested $2bn in Summit in September under a collaboration agreement that gave the drugmaker an 11 per cent equity stake.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.